1. De Martin M, Pecori Giraldi F, Cavagnini F. Cushing's disease. Pituitary 2006;9:279-287.
[CROSSREF] [PUBMED] [PDF]
2. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 2008;93:358-362.
[CROSSREF] [PUBMED] [PDF]
3. Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1996;81:2647-2652.
[PUBMED]
4. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454-2462.
[CROSSREF] [PUBMED] [PMC] [PDF]
5. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001;81:629-683.
[CROSSREF] [PUBMED]
6. Carter CS. Sex differences in oxytocin and vasopressin: implications for autism spectrum disorders? Behav Brain Res 2007;176:170-186.
[CROSSREF] [PUBMED]
7. Qian W, Zhu T, Tang B, Yu S, Hu H, Sun W, et al. Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. J Clin Endocrinol Metab 2014;99:4683-4689.
[CROSSREF] [PUBMED]
8. Breuil V, Panaia-Ferrari P, Fontas E, Roux C, Kolta S, Eastell R, et al. Oxytocin, a new determinant of bone mineral density in post-menopausal women: analysis of the OPUS cohort. J Clin Endocrinol Metab 2014;99:E634-E641.
[CROSSREF] [PUBMED] [PDF]
9. Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 2001;50:609-613.
[CROSSREF] [PUBMED]
10. Kiss A, Mikkelsen JD. Oxytocin: anatomy and functional assignments. A minireview. Endocr Regul 2005;39:97-105.
[PUBMED]
11. Yu Q, Ji R, Gao X, Fu J, Guo W, Song X, et al. Oxytocin is expressed by both intrinsic sensory and secretomotor neurons in the enteric nervous system of guinea pig. Cell Tissue Res 2011;344:227-237.
[CROSSREF] [PUBMED] [PDF]
12. Amico JA, Tenicela R, Johnston J, Robinson AG. A time-dependent peak of oxytocin exists in cerebrospinal fluid but not in plasma of humans. J Clin Endocrinol Metab 1983;57:947-951.
[CROSSREF] [PUBMED] [PDF]
13. Zingg HH, Laporte SA. The oxytocin receptor. Trends Endocrinol Metab 2003;14:222-227.
[CROSSREF]
14. Cassoni P, Sapino A, Marrocco T, Chini B, Bussolati G. Oxytocin and oxytocin receptors in cancer cells and proliferation. J Neuroendocrinol 2004;16:362-364.
[CROSSREF]
15. Imanieh MH, Bagheri F, Alizadeh AM, Ashkani-Esfahani S. Oxytocin has therapeutic effects on cancer, a hypothesis. Eur J Pharmacol 2014;741:112-123.
[CROSSREF] [PUBMED]
16. Cassoni P, Sapino A, Munaron L, Deaglio S, Chini B, Graziani A, et al. Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. Endocrinology 2001;142:1130-1136.
[CROSSREF] [PUBMED] [PDF]
17. Pequeux C, Breton C, Hendrick JC, Hagelstein MT, Martens H, Winkler R, et al. Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/paracrine signaling. Cancer Res 2002;62:4623-4629.
[PUBMED]
18. Cassoni P, Fulcheri E, Carcangiu ML, Stella A, Deaglio S, Bussolati G. Oxytocin receptors in human adenocarcinomas of the endometrium: presence and biological significance. J Pathol 2000;190:470-477.
[CROSSREF] [PUBMED]
19. Morita T, Shibata K, Kikkawa F, Kajiyama H, Ino K, Mizutani S. Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer 2004;109:525-532.
[CROSSREF] [PUBMED]
20. Petersson M. Opposite effects of oxytocin on proliferation of osteosarcoma cell lines. Regul Pept 2008;150:50-54.
[CROSSREF] [PUBMED]
21. Taylor AH, Ang VT, Jenkins JS, Silverlight JJ, Coombes RC, Luqmani YA. Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res 1990;50:7882-7886.
[PUBMED]
22. Cassoni P, Sapino A, Fortunati N, Munaron L, Chini B, Bussolati G. Oxytocin inhibits the proliferation of MDA-MB231 human breast-cancer cells via cyclic adenosine monophosphate and protein kinase A. Int J Cancer 1997;72:340-344.
[CROSSREF] [PUBMED]
23. Cassoni P, Sapino A, Stella A, Fortunati N, Bussolati G. Presence and significance of oxytocin receptors in human neuroblastomas and glial tumors. Int J Cancer 1998;77:695-700.
[CROSSREF] [PUBMED]
24. Bakos J, Strbak V, Ratulovska N, Bacova Z. Effect of oxytocin on neuroblastoma cell viability and growth. Cell Mol Neurobiol 2012;32:891-896.
[CROSSREF] [PDF]
25. Whittington K, Connors B, King K, Assinder S, Hogarth K, Nicholson H. The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate. Prostate 2007;67:1132-1142.
[CROSSREF] [PUBMED]
26. Liu JW, Ben-Jonathan N. Prolactin-releasing activity of neurohypophysial hormones: structure-function relationship. Endocrinology 1994;134:114-118.
[CROSSREF] [PUBMED] [PDF]
27. Gonzalez-Iglesias AE, Fletcher PA, Arias-Cristancho JA, Cristancho-Gordo R, Helena CV, Bertram R, et al. Direct stimulatory effects of oxytocin in female rat gonadotrophs and somatotrophs in vitro: comparison with lactotrophs. Endocrinology 2015;156:600-612.
[CROSSREF] [PUBMED] [PDF]
28. Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Annu Rev Pathol 2009;4:97-126.
[CROSSREF] [PUBMED]
29. Langlois F, McCartney S, Fleseriu M. Recent progress in the medical therapy of pituitary tumors. Endocrinol Metab (Seoul) 2017;32:162-170.
[CROSSREF] [PUBMED] [PMC]
30. Dworakowska D, Grossman AB. The molecular pathogenesis of corticotroph tumours. Eur J Clin Invest 2012;42:665-676.
[CROSSREF] [PUBMED]
31. Roussel-Gervais A, Bilodeau S, Vallette S, Berthelet F, Lacroix A, Figarella-Branger D, et al. Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol Endocrinol 2010;24:1835-1845.
[CROSSREF] [PUBMED] [PMC] [PDF]
32. Jankowski M, Broderick TL, Gutkowska J. Oxytocin and cardioprotection in diabetes and obesity. BMC Endocr Disord 2016;16:34.
[CROSSREF] [PUBMED] [PMC] [PDF]
33. Breton C, Pechoux C, Morel G, Zingg HH. Oxytocin receptor messenger ribonucleic acid: characterization, regulation, and cellular localization in the rat pituitary gland. Endocrinology 1995;136:2928-2936.
[CROSSREF] [PDF]
34. Shibasaki T, Masui H. Effects of various neuropeptides on the secretion of proopiomelanocortin-derived peptides by a cultured pituitary adenoma causing Nelson's syndrome. J Clin Endocrinol Metab 1982;55:872-876.
[CROSSREF] [PUBMED] [PDF]
35. Link H, Dayanithi G, Fohr KJ, Gratzl M. Oxytocin at physiological concentrations evokes adrenocorticotropin (ACTH) release from corticotrophs by increasing intracellular free calcium mobilized mainly from intracellular stores. Oxytocin displays synergistic or additive effects on ACTH-releasing factor or arginine vasopressin-induced ACTH secretion, respectively. Endocrinology 1992;130:2183-2191.
[PUBMED]
36. Gibbs DM. Dissociation of oxytocin, vasopressin and corticotropin secretion during different types of stress. Life Sci 1984;35:487-491.
[CROSSREF] [PUBMED]
37. Petersson M, Hulting AL, Uvnas-Moberg K. Oxytocin causes a sustained decrease in plasma levels of corticosterone in rats. Neurosci Lett 1999;264:41-44.
[CROSSREF] [PUBMED]
38. Nakamura K, Fujiwara Y, Mizutani R, Sanbe A, Miyauchi N, Hiroyama M, et al. Effects of vasopressin V1b receptor deficiency on adrenocorticotropin release from anterior pituitary cells in response to oxytocin stimulation. Endocrinology 2008;149:4883-4891.
[CROSSREF] [PUBMED] [PDF]
39. Page SR, Ang VT, Jackson R, White A, Nussey SS, Jenkins JS. The effect of oxytocin infusion on adenohypophyseal function in man. Clin Endocrinol (Oxf) 1990;32:307-313.
[CROSSREF] [PUBMED]
40. Jafarzadeh N, Javeri A, Khaleghi M, Taha MF. Oxytocin improves proliferation and neural differentiation of adipose tissue-derived stem cells. Neurosci Lett 2014;564:105-110.
[CROSSREF]
41. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 2009;16:1329-1338.
[CROSSREF] [PUBMED]
42. Guzzi F, Zanchetta D, Cassoni P, Guzzi V, Francolini M, Parenti M, et al. Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene 2002;21:1658-1667.
[CROSSREF] [PUBMED] [PDF]